News
-
-
PRESS RELEASE
Communiqué de presse : ASH : le rilzabrutinib a apporté un bénéfice significatif aux patients atteints de TPI dans le cadre de la première étude de phase III positive consacrée à un inhibiteur de la BTK
ASH : le rilzabrutinib montre des résultats positifs dans le traitement de la thrombocytopénie immune lors de l'étude LUNA 3. Profil d'efficacité et de sécurité prometteur -
PRESS RELEASE
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted -
-
-
PRESS RELEASE
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025 -
-
-
-
